ID

DB00190|APRD00160||

名称

Carbidopa

描述

Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with [levodopa]. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.[T394] The first approved product by the FDA containing only carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved on 2014.[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination therapy developed by Mayne Pharma in 1992.[L5113]

cas号

28860-95-9

唯一标识码

KR87B45RGH

状态

solid

组

approved,

指示

Carbidopa is indicated with [levodopa] for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.[FDA label] The combination therapy is administered for the reduction of [levodopa]-driven nausea and vomiting.[FDA label] The product of carbidopa should be used in patients where the combination therapy of carbidopa/[levodopa] provide less than the adequate daily dosage.[FDA label] As well carbidopa can be used in patients where the dosages of carbidopa and [levodopa] require individual titration.[FDA label]

药效学

When mixed with [levodopa], carbidopa inhibits the peripheral conversion of [levodopa] to dopamine and the decarboxylation of [oxitriptan] to serotonin by aromatic L-amino acid decarboxylase. This results in an increased amount of [levodopa] and [oxitriptan] available for transport to the central nervous system. Carbidopa also inhibits the metabolism of [levodopa] in the GI tract, thus, increasing the bioavailability of [levodopa].[A13607] The presence of additional units of circulating [levodopa] can increase the effectiveness of the still functional dopaminergic neurons and it has been shown to alleviate symptoms for a time. The action of carbidopa is very important as [levodopa] is able to cross the blood-brain barrier while dopamine cannot.[T28] Hence the administration of carbidopa is essential to prevent the transformation of external [levodopa] to dopamine before reaching the main action site in the brain. The coadministration of carbidopa with [levodopa] has been shown to increase the half-life of [levodopa] more than 1.5 times while increasing the plasma level and decreasing clearance. The combination therapy has also shown an increase of the recovery of [levodopa] in urine instead of dopamine which proves a reduced metabolism. This effect has been highly observed by a significant reduction in [levodopa] requirements and a significant reduction in the presence of side effects such as nausea. It has been observed that the effect of carbidopa is not dose-dependent.[T394]

作用机制

Carbidopa is an inhibitor of the DDC which in order, inhibits the peripheral metabolism of levodopa.[A173935] DDC is very important in the biosynthesis of L-tryptophan to serotonin and the modification of L-DOPA to dopamine.[A13607] DDC can be found in the body periphery and in the blood-brain barrier.[A13607] The action of carbidopa is focused on peripheral DDC as this drug cannot cross the blood-brain barrier.[T28] Hence, it will prevent the metabolism of [levodopa] in the periphery but it will not have any activity on the generation of dopamine in the brain.

毒性

The LD50 of carbidopa is reported to be in the rat of 4810 mg/kg.[MSDS] In animal studies, carbidopa showed no incidences on neoplasia and showed no effect on the fertility status and development.[FDA label] No reports of overdosage have been registered with the carbidopa-only product. In the event of overdosage, immediate gastric lavage is recommended as well as intravenous fluid administration. Continuous electrocardiographic monitoring is required.[FDA label]

代谢

The loss of the hydrazine functional group (probably as molecular nitrogen) represents the major metabolic pathway for carbidopa. There are several metabolites of carbidopa metabolism including 3-(3,4-dihydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methylpropionic acid, 3-(3-hydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methyllactic acid, 3-(3-hydroxyphenyl)-2-methyllactic acid, and 3,4-dihydroxyphenylacetone (1,2).[A274]

吸收

When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed.[L5116] Once absorbed, carbidopa shows bioavailability of 58%.[A173941] A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.[A173944]

半衰期

The reported half-life of carbidopa is of approximately 107 minutes.[A173944]

分类

description:This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
direct-parent:Phenylpropanoic acids
kingdom:Organic compounds
superclass:Phenylpropanoids and polyketides
class:Phenylpropanoic acids
subclass:
alternative-parent:1-hydroxy-2-unsubstituted benzenoids
alternative-parent:1-hydroxy-4-unsubstituted benzenoids
alternative-parent:Alkylhydrazines
alternative-parent:Alpha amino acids and derivatives
alternative-parent:Amphetamines and derivatives
alternative-parent:Carbonyl compounds
alternative-parent:Carboxylic acids
alternative-parent:Catechols
alternative-parent:Hydrocarbon derivatives
alternative-parent:Monocarboxylic acids and derivatives
alternative-parent:Organic oxides
alternative-parent:Organopnictogen compounds
alternative-parent:Phenylpropanes
substituent:1-hydroxy-2-unsubstituted benzenoid
substituent:1-hydroxy-4-unsubstituted benzenoid
substituent:3-phenylpropanoic-acid
substituent:Alkylhydrazine
substituent:Alpha-amino acid or derivatives
substituent:Amphetamine or derivatives
substituent:Aromatic homomonocyclic compound
substituent:Benzenoid
substituent:Carbonyl group
substituent:Carboxylic acid
substituent:Carboxylic acid derivative
substituent:Catechol
substituent:Hydrazine derivative
substituent:Hydrocarbon derivative
substituent:Monocarboxylic acid or derivatives
substituent:Monocyclic benzene moiety
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Phenol
substituent:Phenylpropane

消除途径

In animal studies, 66% of the administered dose of carbidopa was eliminated via the urine while 11% was found in feces. These studies were performed in humans and it was observed a urine excretion covering 50% of the administered dose.[A274]

种类

Amines
D000588
Anti-Dyskinesia Agents
D018726
Anti-Parkinson Drugs
D000978
Aromatic Amino Acid Decarboxylase Inhibitors
D065105
Aromatic L-amino Acid Decarboxylase Inhibitors

Benzene Derivatives
D001555
Biogenic Amines
D001679
Biogenic Monoamines
D015306
Catecholamines
D002395
Catechols
D002396
Central Nervous System Agents
D002491
Drugs that are Mainly Renally Excreted

Enzyme Inhibitors
D004791
Hydrazines
D006834
Phenols
D010636

盐类

DBSALT001834Carbidopa hydrateMNX7R8C5VO38821-49-7QTAOMKOIBXZKND-PPHPATTJSA-N244.2444244.105921632

蛋白质结合

It is widely accepted that the protein binding of carbidopa is 76%. However, more studies are required or the presentation of the source of this information.

清除

The reported clearance rate for the combination therapy of [levodopa]/carbidopa is 51.7 L/h.[A173947]

同义词

language:english; code:; name;(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
language:english; code:; name;(S)-(−)-carbidopa
language:english; code:; name;(S)-carbidopa
language:english; code:; name;(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
language:english; code:inn; name;Carbidopa
language:english; code:; name;Carbidopa (anhydrous)
language:english; code:; name;Carbidopa anhydrous
language:latin; code:inn; name;Carbidopum
language:english; code:; name;L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
language:english; code:; name;L-α-methyldopahydrazine

国际品牌

配送量

The volume of distribution reported for the combination therapy of carbidopa/[levodopa] is of 3.6 L/kg.[A173947] However, carbidopa is widely distributed in the tissues, except in the brain.[L5116] After one hour, carbidopa is found mainly in the kidney, lungs, small intestine and liver.[A274]

产品

name:Aa-levocarb CR
labeller:Aa Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02245211
ema-product-code:
ema-ma-number:
started-marketing-on:2003-11-13
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Aa-levocarb CR
labeller:Aa Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02272873
ema-product-code:
ema-ma-number:
started-marketing-on:2009-02-04
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-levocarb - Tab 10mg/100mg
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:02195933
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-levocarb - Tab 25mg/250mg
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:02195968
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-levocarb-tab 25mg/100mg
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:02195941
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Carbidopa
labeller:Trupharma, Llc
ndc-id:
ndc-product-code:52817-220
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-11-01
ended-marketing-on:2014-08-19
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA203261
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Lupin Pharmaceuticals
ndc-id:
ndc-product-code:43386-980
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-20
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204763
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Novel Laboratories, Inc.
ndc-id:
ndc-product-code:40032-980
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-20
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204763
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0226
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-02-14
ended-marketing-on:2019-01-31
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:NDA017830
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-0007
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1975-05-02
ended-marketing-on:
dosage-form:Powder
strength:1 kg/1kg
route:Not applicable
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Carbidopa
labeller:Oceanside Pharmaceuticals
ndc-id:
ndc-product-code:68682-200
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-04-04
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:NDA017830
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:59651-146
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-10-21
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA211055
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Zydus Pharmaceuticals (USA) Inc.
ndc-id:
ndc-product-code:70710-1221
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-09-06
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA209910
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Edenbridge Pharmaceuticals LLC.
ndc-id:
ndc-product-code:42799-123
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-02-19
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA205304
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:NorthStar Rx LLC
ndc-id:
ndc-product-code:16714-067
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-10-21
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA211055
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Cadila Healthcare Limited
ndc-id:
ndc-product-code:70771-1355
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-09-06
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA209910
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:ANI Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43975-220
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-10
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA203261
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Golden State Medical Supply
ndc-id:
ndc-product-code:51407-314
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-20
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204763
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa
labeller:Ingenus Pharmaceuticals Nj, Llc
ndc-id:
ndc-product-code:52682-045
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-02
ended-marketing-on:2016-03-02
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA205304
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-5659
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-08-18
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-5776
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-06-08
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Caremark L.L.C.
ndc-id:
ndc-product-code:0339-6028
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-02-16
ended-marketing-on:2011-10-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5816
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-12-16
ended-marketing-on:2013-12-18
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2866
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-1334
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-09
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2834
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-09
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:43353-510
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-6254
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-09-30
ended-marketing-on:2012-10-31
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Goldline Laboratories, Inc.
ndc-id:
ndc-product-code:0182-1176
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-05-10
ended-marketing-on:2013-12-11
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5988
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-03
ended-marketing-on:2012-10-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5975
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-03
ended-marketing-on:2012-10-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5994
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-03
ended-marketing-on:2012-10-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Goldline Laboratories, Inc.
ndc-id:
ndc-product-code:0182-1949
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-03
ended-marketing-on:2013-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Preferreed Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-0046
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-04-01
ended-marketing-on:2015-11-12
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-4569
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-10-18
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-4568
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-10-18
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Apotex Corporation
ndc-id:
ndc-product-code:60505-0132
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-06-16
ended-marketing-on:2011-06-30
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA076212
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Apotex Corporation
ndc-id:
ndc-product-code:60505-0131
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-06-16
ended-marketing-on:2011-06-30
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA076212
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-3561
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-4504
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-3537
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-827
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-23
ended-marketing-on:2015-01-23
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-078
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-07-23
ended-marketing-on:2013-07-23
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Teva
ndc-id:
ndc-product-code:0093-0292
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-03-01
ended-marketing-on:2018-07-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Teva
ndc-id:
ndc-product-code:0093-0293
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-04-01
ended-marketing-on:2018-06-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Teva
ndc-id:
ndc-product-code:0093-0294
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-01-01
ended-marketing-on:2018-01-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-8010
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-04-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-8011
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-01-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-037
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-07-23
ended-marketing-on:2013-07-24
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-096
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-07-23
ended-marketing-on:2013-07-23
dosage-form:Tablet
strength:10 mg/1
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-177
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-08-10
ended-marketing-on:2017-01-26
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-455
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-20
ended-marketing-on:2014-03-20
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3829
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:2015-09-15
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3828
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:2015-12-15
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3830
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:2015-12-15
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Impax Generics
ndc-id:
ndc-product-code:0115-3922
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-05-14
ended-marketing-on:2011-11-30
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA076521
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Impax Generics
ndc-id:
ndc-product-code:0115-3911
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-05-14
ended-marketing-on:2011-11-30
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA076521
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-0697
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-19
ended-marketing-on:2013-02-28
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-0680
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-19
ended-marketing-on:2013-02-28
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Lake Erie Medical Dba Quality Care Produts Llc
ndc-id:
ndc-product-code:35356-355
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:2014-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Carilion Materials Management
ndc-id:
ndc-product-code:68151-2887
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-4568
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-23
ended-marketing-on:2016-01-15
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-179
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-08-10
ended-marketing-on:2017-01-26
dosage-form:Tablet, extended release
strength:25 mg/1
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-180
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-07
ended-marketing-on:2017-01-26
dosage-form:Tablet
strength:10 mg/1
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:60687-181
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-01
ended-marketing-on:2016-06-17
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA202323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:60687-174
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-01
ended-marketing-on:2016-06-17
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA202323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-1484
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-01-10
ended-marketing-on:2018-04-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mc Kesson Contract Packaging
ndc-id:
ndc-product-code:76237-129
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:2017-09-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mc Kesson Contract Packaging
ndc-id:
ndc-product-code:76237-130
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-21
ended-marketing-on:2017-09-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mc Kesson Contract Packaging
ndc-id:
ndc-product-code:76237-259
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-10-06
ended-marketing-on:2017-09-30
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:UDL Laboratories, Inc.
ndc-id:
ndc-product-code:51079-861
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-05
ended-marketing-on:2010-02-10
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:UDL Laboratories, Inc.
ndc-id:
ndc-product-code:51079-885
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-05
ended-marketing-on:2010-02-10
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-5051
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-09-18
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078893
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-5052
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-09-18
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078893
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-5053
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-09-18
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078893
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Actavis Pharma, Inc.
ndc-id:
ndc-product-code:0228-2538
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Actavis Pharma, Inc.
ndc-id:
ndc-product-code:0228-2539
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Actavis Pharma, Inc.
ndc-id:
ndc-product-code:0228-2540
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mayne Pharma Inc.
ndc-id:
ndc-product-code:51862-855
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mayne Pharma Inc.
ndc-id:
ndc-product-code:51862-856
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mayne Pharma Inc.
ndc-id:
ndc-product-code:51862-858
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:62756-461
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-23
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:62756-457
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-23
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-186
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-12-15
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078690
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-187
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-12-15
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078690
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-188
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-12-15
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078690
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Golden State Medical Supply
ndc-id:
ndc-product-code:60429-650
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Golden State Medical Supply
ndc-id:
ndc-product-code:60429-651
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Golden State Medical Supply
ndc-id:
ndc-product-code:60429-652
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Golden State Medical Supply
ndc-id:
ndc-product-code:51407-166
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-08-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Golden State Medical Supply
ndc-id:
ndc-product-code:51407-167
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-08-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Golden State Medical Supply
ndc-id:
ndc-product-code:51407-168
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-08-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:ETHEX
ndc-id:
ndc-product-code:58177-383
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-15
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-093
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-07-12
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-094
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-08-24
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-269
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mayne Pharma Inc
ndc-id:
ndc-product-code:51862-077
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-10-24
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-047
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-04-01
ended-marketing-on:2019-04-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Alembic Pharmaceuticals Inc.
ndc-id:
ndc-product-code:62332-332
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-06
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA210341
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Alembic Pharmaceuticals Inc.
ndc-id:
ndc-product-code:62332-333
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-06
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA210341
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Alembic Pharmaceuticals Limited
ndc-id:
ndc-product-code:46708-332
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-06
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA210341
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Alembic Pharmaceuticals Limited
ndc-id:
ndc-product-code:46708-333
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-06
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA210341
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-281
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-08-22
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-282
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-08-22
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6237
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-11
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6238
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-11
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-7886
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-11
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:McKesson Corporation dba RX Pak
ndc-id:
ndc-product-code:65084-107
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:2019-09-17
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:McKesson Corporation dba RX Pak
ndc-id:
ndc-product-code:65084-108
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3419
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Accord Healthcare, Inc.
ndc-id:
ndc-product-code:16729-079
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-06-13
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA202323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Accord Healthcare, Inc.
ndc-id:
ndc-product-code:16729-078
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-06-13
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA202323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Institutional Inc.
ndc-id:
ndc-product-code:51079-884
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-27
ended-marketing-on:2020-08-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-0078
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-0085
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-1133
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8067
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-18
ended-marketing-on:2022-03-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8068
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-18
ended-marketing-on:2022-02-28
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:43353-202
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-02-08
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:43353-327
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2000-04-26
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:67544-672
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-10-06
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Institutional Inc.
ndc-id:
ndc-product-code:51079-978
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-05-14
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Institutional Inc.
ndc-id:
ndc-product-code:51079-923
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-05-14
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-013
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-18
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-017
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-18
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-107
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-108
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:66267-649
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-0088
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2000-04-26
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-0094
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-10-06
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA075091
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Mayne Pharma Inc.
ndc-id:
ndc-product-code:51862-078
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-04-10
ended-marketing-on:2022-04-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Mayne Pharma Inc.
ndc-id:
ndc-product-code:51862-079
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-18
ended-marketing-on:2022-07-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Mayne Pharma Inc.
ndc-id:
ndc-product-code:51862-080
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-18
ended-marketing-on:2022-05-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:BluePoint Laboratories
ndc-id:
ndc-product-code:68001-172
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-22
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA202323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:BluePoint Laboratories
ndc-id:
ndc-product-code:68001-171
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-22
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA202323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8251
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8275
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-4279
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:2012-06-01
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-6779
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-09-01
ended-marketing-on:2016-09-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-152
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-18
ended-marketing-on:2018-01-01
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-153
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-18
ended-marketing-on:2017-12-01
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-154
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-18
ended-marketing-on:2018-01-01
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-5187
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-04-24
ended-marketing-on:2017-05-24
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078690
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-7718
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-19
ended-marketing-on:2018-07-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-7719
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-19
ended-marketing-on:2012-09-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-7720
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-19
ended-marketing-on:2012-04-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-642
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-22
ended-marketing-on:2019-10-11
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-2538
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-06
ended-marketing-on:2017-05-24
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Apotex Corp.
ndc-id:
ndc-product-code:60505-0128
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-09
ended-marketing-on:2012-03-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA077120
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Apotex Corp.
ndc-id:
ndc-product-code:60505-0129
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-09
ended-marketing-on:2012-06-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA077120
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Apotex Corp.
ndc-id:
ndc-product-code:60505-0130
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-09
ended-marketing-on:2012-02-28
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA077120
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4067
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:2019-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries Limited
ndc-id:
ndc-product-code:62756-186
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-08-14
ended-marketing-on:2016-08-31
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078690
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries Limited
ndc-id:
ndc-product-code:62756-187
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-08-14
ended-marketing-on:2016-08-31
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078690
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries Limited
ndc-id:
ndc-product-code:62756-188
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-08-14
ended-marketing-on:2016-08-31
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA078690
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-6753
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:2017-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-9684
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-04-23
ended-marketing-on:2019-07-09
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-4688
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-07-12
ended-marketing-on:2020-08-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:62756-517
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:62756-518
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:62756-519
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-046
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-03-01
ended-marketing-on:2019-04-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073618
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-048
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-01-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA073607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5360
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-05
ended-marketing-on:2011-08-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090324
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-2240
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2909
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-14
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and levodopa
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2908
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-14
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA074260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3857
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078536
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8180
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-23
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa and Levodopa
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8181
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-23
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:ANDA077828
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa Tablets, 25 mg
labeller:Av Kare, Inc.
ndc-id:
ndc-product-code:42291-188
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-03
ended-marketing-on:2016-09-19
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204291
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa Tablets, 25 mg
labeller:Alvogen Inc.
ndc-id:
ndc-product-code:47781-332
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-25
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204291
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa Tablets, 25 mg
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:51407-158
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-08
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204291
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt
ndc-id:
ndc-product-code:55648-782
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt
ndc-id:
ndc-product-code:55648-783
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt
ndc-id:
ndc-product-code:55648-784
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt
ndc-id:
ndc-product-code:55648-785
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt
ndc-id:
ndc-product-code:55648-786
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt
ndc-id:
ndc-product-code:55648-787
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, levodopa and entacapone
labeller:Sun Pharma Global FZE
ndc-id:
ndc-product-code:47335-909
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-05-22
ended-marketing-on:2018-03-31
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA079085
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, levodopa and entacapone
labeller:Sun Pharma Global FZE
ndc-id:
ndc-product-code:47335-910
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-05-22
ended-marketing-on:2018-03-31
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA079085
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-8300
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-02-12
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-8301
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-28
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-8302
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-28
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-8303
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-28
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-8304
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-28
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-8305
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-28
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, levodopa and entacapone
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-001
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-02
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, levodopa and entacapone
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-002
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-02
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, levodopa and entacapone
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-003
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-04-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, levodopa and entacapone
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-004
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-02
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, levodopa and entacapone
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-005
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-04-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, levodopa and entacapone
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-006
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-02
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt USA LLC.
ndc-id:
ndc-product-code:64679-782
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt USA LLC.
ndc-id:
ndc-product-code:64679-783
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt USA LLC.
ndc-id:
ndc-product-code:64679-784
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt USA LLC.
ndc-id:
ndc-product-code:64679-785
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt USA LLC.
ndc-id:
ndc-product-code:64679-786
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa and Entacapone
labeller:Wockhardt USA LLC.
ndc-id:
ndc-product-code:64679-787
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa, and Entacapone
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5669
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-18
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa, and Entacapone
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5654
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-18
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa, and Entacapone
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5641
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-18
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa, and Entacapone
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5637
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-18
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa, and Entacapone
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5625
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-18
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Carbidopa, Levodopa, and Entacapone
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5613
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-18
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dom-levo-carbidopa
labeller:Dominion Pharmacal
ndc-id:
ndc-product-code:
dpd-id:02247606
ema-product-code:
ema-ma-number:
started-marketing-on:2003-05-22
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Duodopa
labeller:Abbvie
ndc-id:
ndc-product-code:
dpd-id:02292165
ema-product-code:
ema-ma-number:
started-marketing-on:2008-11-10
ended-marketing-on:
dosage-form:Gel
strength:
route:Enteral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Duopa
labeller:AbbVie Inc.
ndc-id:
ndc-product-code:0074-3012
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-15
ended-marketing-on:
dosage-form:Suspension
strength:
route:Enteral
fda-application-number:NDA203952
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Levodopa-carbidopa CR
labeller:Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:02421488
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Levodopa-carbidopa CR
labeller:Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:02421496
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lodosyn
labeller:Bristol Myers Squibb Pharma Company
ndc-id:
ndc-product-code:0056-0511
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-01
ended-marketing-on:2013-10-19
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:NDA017830
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lodosyn
labeller:Bausch Health US, LLC
ndc-id:
ndc-product-code:25010-711
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-04-13
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:NDA017830
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lodosyn
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0125
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-09-25
ended-marketing-on:2017-06-30
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:NDA017830
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lodosyn
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-0711
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-13
ended-marketing-on:2017-05-24
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:NDA017830
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Mint-levocarb
labeller:Mint Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02457962
ema-product-code:
ema-ma-number:
started-marketing-on:2016-11-03
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mint-levocarb
labeller:Mint Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02457954
ema-product-code:
ema-ma-number:
started-marketing-on:2016-11-03
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mint-levocarb
labeller:Mint Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02457970
ema-product-code:
ema-ma-number:
started-marketing-on:2016-11-23
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Nu-levocarb - Tab 10mg/100mg
labeller:Nu Pharm Inc
ndc-id:
ndc-product-code:
dpd-id:02182831
ema-product-code:
ema-ma-number:
started-marketing-on:1996-12-31
ended-marketing-on:2012-09-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Nu-levocarb - Tab 25 Mg/100 mg
labeller:Nu Pharm Inc
ndc-id:
ndc-product-code:
dpd-id:02182823
ema-product-code:
ema-ma-number:
started-marketing-on:1996-12-31
ended-marketing-on:2012-09-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Nu-levocarb - Tablets 25 Mg/250 mg
labeller:Nu Pharm Inc
ndc-id:
ndc-product-code:
dpd-id:02182858
ema-product-code:
ema-ma-number:
started-marketing-on:1996-12-31
ended-marketing-on:2012-09-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/001
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/002
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/003
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/004
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/005
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/006
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/007
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/008
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/009
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/010
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/011
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Numient
labeller:Amneal Pharma Europe Ltd
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002611
ema-ma-number:EU/1/15/1044/012
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Parcopa
labeller:Schwarz Pharma
ndc-id:
ndc-product-code:0091-3342
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-11-05
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Parcopa
labeller:Schwarz Pharma
ndc-id:
ndc-product-code:0091-3341
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-11-05
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Parcopa
labeller:Schwarz Pharma
ndc-id:
ndc-product-code:0091-3343
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-11-05
ended-marketing-on:
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Parcopa
labeller:Jazz Pharmaceuticals
ndc-id:
ndc-product-code:18860-342
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-09-01
ended-marketing-on:2014-10-31
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA076699
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Parcopa
labeller:Jazz Pharmaceuticals
ndc-id:
ndc-product-code:18860-341
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-19
ended-marketing-on:2014-08-31
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA076699
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Parcopa
labeller:Jazz Pharmaceuticals
ndc-id:
ndc-product-code:18860-343
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-09-01
ended-marketing-on:2014-10-31
dosage-form:Tablet, orally disintegrating
strength:
route:Oral
fda-application-number:ANDA076699
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pro-lecarb-100/10 - Tab
labeller:Pro Doc Limitee
ndc-id:
ndc-product-code:
dpd-id:02223287
ema-product-code:
ema-ma-number:
started-marketing-on:1997-12-04
ended-marketing-on:2003-07-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pro-lecarb-100/25 - Tab
labeller:Pro Doc Limitee
ndc-id:
ndc-product-code:
dpd-id:02223295
ema-product-code:
ema-ma-number:
started-marketing-on:1997-08-06
ended-marketing-on:2003-07-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pro-levocarb - 100/25
labeller:Pro Doc Limitee
ndc-id:
ndc-product-code:
dpd-id:02311178
ema-product-code:
ema-ma-number:
started-marketing-on:2008-07-04
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ratio-levodopa/carbidopa
labeller:Ratiopharm Inc Division Of Teva Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02126184
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:2006-08-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ratio-levodopa/carbidopa
labeller:Ratiopharm Inc Division Of Teva Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02126168
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:2006-08-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ratio-levodopa/carbidopa
labeller:Ratiopharm Inc Division Of Teva Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02126176
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:2006-08-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Rytary
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:64896-661
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-12
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:NDA203312
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Rytary
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:64896-662
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-12
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:NDA203312
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Rytary
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:64896-663
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-12
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:NDA203312
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Rytary
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:64896-664
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-12
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:NDA203312
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sandoz Levodopa-carbidopa-entacapone
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02498855
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sandoz Levodopa-carbidopa-entacapone
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02498863
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sandoz Levodopa-carbidopa-entacapone
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02498871
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sandoz Levodopa-carbidopa-entacapone
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02498898
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sandoz Levodopa-carbidopa-entacapone
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02498901
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sinemet
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-1544
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-08-08
ended-marketing-on:2000-09-19
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-1270
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-08-08
ended-marketing-on:2000-09-19
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Bristol Myers Squibb Pharma Company
ndc-id:
ndc-product-code:0056-0650
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-01
ended-marketing-on:2013-09-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Bristol Myers Squibb Pharma Company
ndc-id:
ndc-product-code:0056-0647
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-01
ended-marketing-on:2012-09-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Bristol Myers Squibb Pharma Company
ndc-id:
ndc-product-code:0056-0654
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-01
ended-marketing-on:2014-05-18
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-3915
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1975-05-02
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-3916
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1975-05-02
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-3917
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1975-05-02
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-6722
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-03
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-6724
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-03
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-6723
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-03
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA017555
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet 100/10
labeller:Merck Ltd.
ndc-id:
ndc-product-code:
dpd-id:00355658
ema-product-code:
ema-ma-number:
started-marketing-on:1979-12-31
ended-marketing-on:2017-06-16
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sinemet 100/25
labeller:Merck Ltd.
ndc-id:
ndc-product-code:
dpd-id:00513997
ema-product-code:
ema-ma-number:
started-marketing-on:1980-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sinemet 250/25
labeller:Merck Ltd.
ndc-id:
ndc-product-code:
dpd-id:00328219
ema-product-code:
ema-ma-number:
started-marketing-on:1975-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sinemet CR
labeller:Bristol Myers Squibb Pharma Company
ndc-id:
ndc-product-code:0056-0521
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-01
ended-marketing-on:2014-06-22
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:NDA019856
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet CR
labeller:Bristol Myers Squibb Pharma Company
ndc-id:
ndc-product-code:0056-0601
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-01
ended-marketing-on:2012-10-31
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:NDA019856
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet CR
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-1882
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-10-05
ended-marketing-on:2005-09-19
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:NDA019856
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet CR
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-3918
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-05-30
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:NDA019856
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet CR
labeller:Merck Sharp & Dohme Corp.
ndc-id:
ndc-product-code:0006-3919
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-05-30
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:NDA019856
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sinemet CR 100/25
labeller:Merck Ltd.
ndc-id:
ndc-product-code:
dpd-id:02028786
ema-product-code:
ema-ma-number:
started-marketing-on:1993-12-31
ended-marketing-on:2019-10-31
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sinemet CR 200/50
labeller:Merck Ltd.
ndc-id:
ndc-product-code:
dpd-id:00870935
ema-product-code:
ema-ma-number:
started-marketing-on:1991-12-31
ended-marketing-on:2019-02-22
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/001
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/002
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/003
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/004
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/005
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/006
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/007
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/008
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/009
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/010
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/011
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/012
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/013
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/014
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/015
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/016
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/017
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/018
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/019
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/020
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/021
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/022
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/023
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/024
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/025
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/026
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/027
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/028
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/029
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/030
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/031
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/032
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/033
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/034
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/035
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/036
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/037
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Orion Corporation
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/000511
ema-ma-number:EU/1/03/260/038
started-marketing-on:2003-10-17
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Stalevo
labeller:Novartis Pharmaceuticals Corporation
ndc-id:
ndc-product-code:0078-0407
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-06-11
ended-marketing-on:2022-05-31
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Novartis Pharmaceuticals Corporation
ndc-id:
ndc-product-code:0078-0544
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-09-26
ended-marketing-on:2021-11-30
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Novartis Pharmaceuticals Corporation
ndc-id:
ndc-product-code:0078-0408
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-06-11
ended-marketing-on:2021-08-31
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Novartis Pharmaceuticals Corporation
ndc-id:
ndc-product-code:0078-0545
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-09-26
ended-marketing-on:2021-12-31
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Novartis Pharmaceuticals Corporation
ndc-id:
ndc-product-code:0078-0409
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-06-11
ended-marketing-on:2022-03-31
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Novartis Pharmaceuticals Corporation
ndc-id:
ndc-product-code:0078-0527
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-02
ended-marketing-on:2022-03-31
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Almatica Pharma LLC
ndc-id:
ndc-product-code:52427-805
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Almatica Pharma LLC
ndc-id:
ndc-product-code:52427-809
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Almatica Pharma LLC
ndc-id:
ndc-product-code:52427-816
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Almatica Pharma LLC
ndc-id:
ndc-product-code:52427-827
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Almatica Pharma LLC
ndc-id:
ndc-product-code:52427-834
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Almatica Pharma LLC
ndc-id:
ndc-product-code:52427-842
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:NDA021485
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Stalevo
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02305933
ema-product-code:
ema-ma-number:
started-marketing-on:2008-04-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Stalevo
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02305941
ema-product-code:
ema-ma-number:
started-marketing-on:2008-04-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Stalevo
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02305968
ema-product-code:
ema-ma-number:
started-marketing-on:2008-04-28
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Stalevo
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02337827
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-20
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Stalevo
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02337835
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-20
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-levocarbidopa
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02244494
ema-product-code:
ema-ma-number:
started-marketing-on:2002-07-05
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-levocarbidopa
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02244495
ema-product-code:
ema-ma-number:
started-marketing-on:2002-07-05
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-levocarbidopa
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02244496
ema-product-code:
ema-ma-number:
started-marketing-on:2002-07-05
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD

混合物

name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Numient
ingredients:Carbidopa + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Parcopa
ingredients:Carbidopa + Levodopa
name:Parcopa
ingredients:Carbidopa + Levodopa
name:Parcopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Sinemet CR
ingredients:Carbidopa + Levodopa
name:Sinemet CR
ingredients:Carbidopa + Levodopa
name:Lodosyn
ingredients:Carbidopa
name:Sinemet CR
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa Tablets, 25 mg
ingredients:Carbidopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa
name:Parcopa
ingredients:Carbidopa + Levodopa
name:Parcopa
ingredients:Carbidopa + Levodopa
name:Parcopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa
name:Carbidopa and levodopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa, levodopa and entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, levodopa and entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa, levodopa and entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, levodopa and entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, levodopa and entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, levodopa and entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, levodopa and entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, levodopa and entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa Tablets, 25 mg
ingredients:Carbidopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Sinemet CR
ingredients:Carbidopa + Levodopa
name:Sinemet CR
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa
ingredients:Carbidopa
name:Rytary
ingredients:Carbidopa + Levodopa
name:Rytary
ingredients:Carbidopa + Levodopa
name:Rytary
ingredients:Carbidopa + Levodopa
name:Rytary
ingredients:Carbidopa + Levodopa
name:Carbidopa, Levodopa, and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa, and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa, and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa, and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa, and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa, and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa Tablets, 25 mg
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa, Levodopa and Entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Sinemet
ingredients:Carbidopa + Levodopa
name:Carbidopa
ingredients:Carbidopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Lodosyn
ingredients:Carbidopa
name:Duopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Lodosyn
ingredients:Carbidopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa
ingredients:Carbidopa
name:Lodosyn
ingredients:Carbidopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Carbidopa and Levodopa
ingredients:Carbidopa + Levodopa
name:Sinemet CR 200/50
ingredients:Carbidopa + Levodopa
name:Sinemet CR 100/25
ingredients:Carbidopa + Levodopa
name:Apo-levocarb - Tab 10mg/100mg
ingredients:Carbidopa + Levodopa
name:Apo-levocarb - Tab 25mg/250mg
ingredients:Carbidopa + Levodopa
name:Apo-levocarb-tab 25mg/100mg
ingredients:Carbidopa + Levodopa
name:Sinemet 250/25
ingredients:Carbidopa + Levodopa
name:Sinemet 100/25
ingredients:Carbidopa + Levodopa
name:Teva-levocarbidopa
ingredients:Carbidopa + Levodopa
name:Teva-levocarbidopa
ingredients:Carbidopa + Levodopa
name:Teva-levocarbidopa
ingredients:Carbidopa + Levodopa
name:Aa-levocarb CR
ingredients:Carbidopa + Levodopa
name:Aa-levocarb CR
ingredients:Carbidopa + Levodopa
name:Duodopa
ingredients:Carbidopa + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Pro-levocarb - 100/25
ingredients:Carbidopa + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Stalevo
ingredients:Carbidopa + Entacapone + Levodopa
name:Levodopa-carbidopa CR
ingredients:Carbidopa + Levodopa
name:Levodopa-carbidopa CR
ingredients:Carbidopa + Levodopa
name:Ratio-levodopa/carbidopa
ingredients:Carbidopa + Levodopa
name:Ratio-levodopa/carbidopa
ingredients:Carbidopa + Levodopa
name:Ratio-levodopa/carbidopa
ingredients:Carbidopa + Levodopa
name:Nu-levocarb - Tablets 25 Mg/250 mg
ingredients:Carbidopa + Levodopa
name:Nu-levocarb - Tab 10mg/100mg
ingredients:Carbidopa + Levodopa
name:Nu-levocarb - Tab 25 Mg/100 mg
ingredients:Carbidopa + Levodopa
name:Pro-lecarb-100/10 - Tab
ingredients:Carbidopa + Levodopa
name:Pro-lecarb-100/25 - Tab
ingredients:Carbidopa + Levodopa
name:Mint-levocarb
ingredients:Carbidopa + Levodopa
name:Sinemet 100/10
ingredients:Carbidopa + Levodopa
name:Dom-levo-carbidopa
ingredients:Carbidopa + Levodopa
name:Mint-levocarb
ingredients:Carbidopa + Levodopa
name:Mint-levocarb
ingredients:Carbidopa + Levodopa
name:Sandoz Levodopa-carbidopa-entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Sandoz Levodopa-carbidopa-entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Sandoz Levodopa-carbidopa-entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Sandoz Levodopa-carbidopa-entacapone
ingredients:Carbidopa + Entacapone + Levodopa
name:Sandoz Levodopa-carbidopa-entacapone
ingredients:Carbidopa + Entacapone + Levodopa

包装者

name:Aton Pharma Inc.
url:http://www.atonrx.com
name:Bristol-Myers Squibb Co.
url:http://www.bms.com
name:Kaiser Foundation Hospital
url:
name:Medisca Inc.
url:http://www.medisca.com
name:Merck & Co.
url:http://www.merck.com

生产者

generic:否; url:; name;Aton pharma inc

价格

Lodosyn 25 mg tablet
2.53(单位：USD）
tablet
Carbidopa powder
27.54(单位：USD）
g

受影响的生物体

Humans and other mammals

剂量

form:Powder
route:Not applicable
strength:1 kg/1kg
form:Tablet
route:Oral
strength:
form:Tablet
route:Oral
strength:10 mg/1
form:Tablet, extended release
route:Oral
strength:
form:Tablet, extended release
route:Oral
strength:25 mg/1
form:Tablet
route:Oral
strength:25 mg
form:Tablet, film coated
route:Oral
strength:25 mg
form:Tablet, film coated
route:Oral
strength:12.5 mg
form:Tablet
route:Oral
strength:100 mg/1
form:Tablet, extended release
route:Oral
strength:100 mg/1
form:Tablet
route:Oral
strength:200 mg/1
form:Tablet, extended release
route:Oral
strength:200 mg/1
form:Gel
route:Enteral
strength:
form:Gel
route:Intraileal
strength:5 mg/1mL
form:Gel
route:Enteral
strength:20 mg/ml
form:Gel
route:Intraduodenal
strength:20 mg/ml
form:Suspension
route:Enteral
strength:
form:Tablet
route:Oral
strength:100 mg
form:Tablet
route:Oral
strength:250 mg
form:Tablet, extended release
route:Oral
strength:100 mg
form:Tablet, extended release
route:Oral
strength:200 mg
form:Tablet, film coated
route:Oral
strength:100 mg
form:Tablet, film coated
route:Oral
strength:125 mg
form:Tablet, film coated
route:Oral
strength:150 mg
form:Tablet, film coated
route:Oral
strength:175 mg
form:Tablet, film coated
route:Oral
strength:200 mg
form:Tablet, film coated
route:Oral
strength:50 mg
form:Tablet, film coated
route:Oral
strength:75 mg
form:Tablet
route:Oral
strength:200 mg
form:Tablet, film coated
route:Oral
strength:43.75 mg
form:Tablet, film coated
route:Oral
strength:18.75 mg
form:Tablet, coated
route:Oral
strength:175 MG
form:Tablet, coated
route:Oral
strength:100 mg
form:Tablet, coated
route:Oral
strength:125 mg
form:Tablet, coated
route:Oral
strength:150 mg
form:Tablet, coated
route:Oral
strength:200 mg
form:Tablet, coated
route:Oral
strength:50 mg
form:Tablet, coated
route:Oral
strength:75 mg
form:Tablet
route:Oral
strength:25 mg/1
form:Capsule
route:Oral
strength:100 MG
form:Capsule
route:Oral
strength:200 MG
form:Tablet, for suspension
route:Oral
strength:100 MG
form:Capsule
route:Oral
strength:145 MG
form:Capsule
route:Oral
strength:195 MG
form:Capsule
route:Oral
strength:245 MG
form:Capsule
route:Oral
strength:95 MG
form:Capsule, extended release
route:Oral
strength:
form:Tablet, orally disintegrating
route:Oral
strength:
form:Tablet
route:Oral
strength:50 mg
form:Tablet, extended release
route:Oral
strength:50 mg
form:Tablet
route:Oral
strength:12.5 MG
form:Tablet, coated
route:Oral
strength:12.5 mg
form:Tablet, coated
route:Oral
strength:25 mg
form:Tablet, coated
route:Oral
strength:37.5 mg
form:Tablet, film coated
route:Oral
strength:
form:Tablet, film coated
route:Oral
strength:40.5 mg
form:Tablet, film coated
route:Oral
strength:31.25 mg
form:Tablet, film coated
route:Oral
strength:37.5 mg
form:Tablet, coated
route:Oral
strength:31.25 mg
form:Tablet, for suspension
route:Oral
strength:1.25 mg

atc代码

fda标签

//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00190.pdf?1547850615

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00190.pdf?1265922738

专利

number:6500867
country:United States
approved:2002-12-31
expires:2020-06-29
pediatric-extension:否
number:6797732
country:United States
approved:2004-09-28
expires:2020-06-29
pediatric-extension:否
number:9089607
country:United States
approved:2015-07-28
expires:2028-12-26
pediatric-extension:否
number:8377474
country:United States
approved:2013-02-19
expires:2028-12-26
pediatric-extension:否
number:8454998
country:United States
approved:2013-06-04
expires:2028-12-26
pediatric-extension:否
number:7094427
country:United States
approved:2006-08-22
expires:2022-05-29
pediatric-extension:否
number:8557283
country:United States
approved:2013-10-15
expires:2028-12-26
pediatric-extension:否
number:9089608
country:United States
approved:2015-07-28
expires:2028-12-26
pediatric-extension:否
number:9463246
country:United States
approved:2016-10-11
expires:2028-12-26
pediatric-extension:否
number:9533046
country:United States
approved:2017-01-03
expires:2028-12-26
pediatric-extension:否
number:9901640
country:United States
approved:2018-02-27
expires:2028-12-26
pediatric-extension:否

食物相互作用

药物相互作用

DB06262
The serum concentration of norepinephrine, an active metabolite of Droxidopa, can be decreased when used in combination with Carbidopa.
DB00422
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Carbidopa.
DB06701
The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Carbidopa.
DB01233
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Metoclopramide.
DB00246
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Ziprasidone.
DB00334
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Olanzapine.
DB00363
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Clozapine.
DB00734
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Risperidone.
DB01224
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Quetiapine.
DB01238
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Aripiprazole.
DB01267
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Paliperidone.
DB04888
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Bifeprunox.
DB04946
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Iloperidone.
DB05316
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Pimavanserin.
DB06016
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Cariprazine.
DB06077
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Lumateperone.
DB06144
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Sertindole.
DB06216
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Asenapine.
DB08815
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Lurasidone.
DB08922
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Perospirone.
DB09128
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Brexpiprazole.
DB09223
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Blonanserin.
DB09224
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Melperone.
DB09225
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Zotepine.
DB09226
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Brilaroxazine.
DB06288
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Amisulpride.
DB00408
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Loxapine.
DB00420
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Promazine.
DB00433
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Prochlorperazine.
DB00450
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Droperidol.
DB00477
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Chlorpromazine.
DB00502
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Haloperidol.
DB00623
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Fluphenazine.
DB00679
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Thioridazine.
DB00831
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Trifluoperazine.
DB00850
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Perphenazine.
DB00875
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Flupentixol.
DB00933
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Mesoridazine.
DB01100
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Pimozide.
DB01239
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Chlorprothixene.
DB01403
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Methotrimeprazine.
DB01608
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Periciazine.
DB01618
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Molindone.
DB01622
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Thioproperazine.
DB01623
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Thiothixene.
DB01624
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Zuclopenthixol.
DB11376
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Azaperone.
DB01156
The risk or severity of adverse effects can be increased when Bupropion is combined with Carbidopa.
DB00091
Cyclosporine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00159
Icosapent may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00229
Cefotiam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00244
Mesalazine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00267
Cefmenoxime may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00274
Cefmetazole may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00282
Pamidronic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00300
Tenofovir disoproxil may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00328
Indomethacin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00369
Cidofovir may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00384
Triamterene may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00430
Cefpiramide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00438
Ceftazidime may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00447
Loracarbef may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00456
Cefalotin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00461
Nabumetone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00465
Ketorolac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00469
Tenoxicam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00482
Celecoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00493
Cefotaxime may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00500
Tolmetin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00529
Foscarnet may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00533
Rofecoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00554
Piroxicam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00563
Methotrexate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00567
Cephalexin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00573
Fenoprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00577
Valaciclovir may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00580
Valdecoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00586
Diclofenac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00605
Sulindac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00626
Bacitracin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00681
Amphotericin B may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00689
Cephaloglycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00712
Flurbiprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00718
Adefovir dipivoxil may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00738
Pentamidine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00742
Mannitol may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00749
Etodolac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00784
Mefenamic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00787
Acyclovir may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00788
Naproxen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00795
Sulfasalazine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00812
Phenylbutazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00814
Meloxicam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00821
Carprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00833
Cefaclor may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00861
Diflunisal may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00864
Tacrolimus may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00903
Etacrynic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00923
Ceforanide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00936
Salicylic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00939
Meclofenamic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00945
Acetylsalicylic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00958
Carboplatin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00991
Oxaprozin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01009
Ketoprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01014
Balsalazide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01050
Ibuprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01066
Cefditoren may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01072
Atazanavir may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01111
Colistimethate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01112
Cefuroxime may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01139
Cefapirin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01140
Cefadroxil may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01150
Cefprozil may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01212
Ceftriaxone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01250
Olsalazine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01283
Lumiracoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01326
Cefamandole may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01327
Cefazolin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01328
Cefonicid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01329
Cefoperazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01330
Cefotetan may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01331
Cefoxitin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01332
Ceftizoxime may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01333
Cefradine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01397
Magnesium salicylate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01399
Salsalate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01401
Choline magnesium trisalicylate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01413
Cefepime may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01414
Cefacetrile may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01415
Ceftibuten may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01416
Cefpodoxime may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01419
Antrafenine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01424
Aminophenazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01435
Antipyrine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01600
Tiaprofenic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01601
Lopinavir may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01628
Etoricoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB02247
Hydrolyzed Cephalothin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB03450
Cephalothin Group may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB03585
Oxyphenbutazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04570
Latamoxef may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04743
Nimesulide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04812
Benoxaprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04817
Metamizole may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04828
Zomepirac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04918
Ceftobiprole may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB05095
Cimicoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB06590
Ceftaroline fosamil may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB06725
Lornoxicam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB06736
Aceclofenac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB06737
Zaltoprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB07402
Azapropazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08439
Parecoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08797
Salicylamide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08940
Kebuzone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08942
Isoxicam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08951
Indoprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08955
Ibuproxam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08976
Floctafenine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08981
Fenbufen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08984
Etofenamate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08991
Epirizole may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09008
Cefaloridine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09062
Cefminox may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09084
Benzydamine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09213
Dexibuprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09214
Dexketoprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09215
Droxicam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09216
Tolfenamic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09217
Firocoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09218
Clonixin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09285
Morniflumate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09288
Propacetamol may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09295
Talniflumate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09299
Tenofovir alafenamide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB11367
Cefroxadine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB11455
Robenacoxib may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB11466
Tepoxalin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB11518
Flunixin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB11935
Flomoxef may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB12151
Brincidofovir may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB12445
Nitroaspirin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB12545
Indobufen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13001
Tinoridine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13167
Alclofenac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13217
Fentiazac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13232
Suxibuzone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13266
Cefatrizine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13286
Bumadizone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13314
Alminoprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13371
Difenpiramide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13407
Nifenazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13432
Lonazolac may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13461
Cefcapene may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13470
Cefodizime may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13481
Tenidap may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13499
Cefsulodin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13504
Cefetamet may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13524
Propyphenazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13527
Proglumetacin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13538
Guacetisal may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13544
Ethenzamide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13612
Carbaspirin calcium may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13629
Mofebutazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13638
Cefbuperazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13649
Proquazone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13657
Benorilate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13667
Cefozopran may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13682
Cefpirome may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13722
Pirprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13778
Cefazedone may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13783
Acemetacin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13821
Ceftezole may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13860
Imidazole salicylate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13868
Adefovir may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB14059
SC-236 may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB14060
NS-398 may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB14126
Tenofovir may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB14713
Inotersen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01438
Phenazopyridine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB15066
Givosiran may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01356
Lithium cation may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB14507
Lithium citrate may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB09212
Loxoprofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00452
Framycetin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01421
Paromomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04263
Geneticin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04626
Apramycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04808
Neamine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB08437
Puromycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB11512
Dihydrostreptomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB11520
Hygromycin B may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00007
Leuprolide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00014
Goserelin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00017
Salmon calcitonin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00035
Desmopressin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00041
Aldesleukin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00080
Daptomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00081
Tositumomab may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00115
Cyanocobalamin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00158
Folic acid may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00165
Pyridoxine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00176
Fluvoxamine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00181
Baclofen may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00182
Amphetamine may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00185
Cevimeline may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00186
Lorazepam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00193
Carbidopa may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00196
Carbidopa may decrease the excretion rate of Fluconazole which could result in a higher serum level.
DB00198
Carbidopa may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00200
Carbidopa may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00208
Carbidopa may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
DB00213
Carbidopa may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
DB00225
Carbidopa may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00230
Carbidopa may decrease the excretion rate of Pregabalin which could result in a higher serum level.
DB00231
Carbidopa may decrease the excretion rate of Temazepam which could result in a higher serum level.
DB00235
Carbidopa may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00237
Carbidopa may decrease the excretion rate of Butabarbital which could result in a higher serum level.
DB00243
Carbidopa may decrease the excretion rate of Ranolazine which could result in a higher serum level.
DB00245
Carbidopa may decrease the excretion rate of Benzatropine which could result in a higher serum level.
DB00254
Carbidopa may decrease the excretion rate of Doxycycline which could result in a higher serum level.
DB00262
Carbidopa may decrease the excretion rate of Carmustine which could result in a higher serum level.
DB00271
Carbidopa may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
DB00273
Carbidopa may decrease the excretion rate of Topiramate which could result in a higher serum level.
DB00279
Carbidopa may decrease the excretion rate of Liothyronine which could result in a higher serum level.
DB00280
Carbidopa may decrease the excretion rate of Disopyramide which could result in a higher serum level.
DB00284
Carbidopa may decrease the excretion rate of Acarbose which could result in a higher serum level.
DB00285
Carbidopa may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
DB00286
Carbidopa may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00289
Carbidopa may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
DB00290
Carbidopa may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DB00292
Carbidopa may decrease the excretion rate of Etomidate which could result in a higher serum level.
DB00294
Carbidopa may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
DB00296
Carbidopa may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00303
Carbidopa may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00308
Carbidopa may decrease the excretion rate of Ibutilide which could result in a higher serum level.
DB00312
Carbidopa may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
DB00316
Carbidopa may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
DB00319
Carbidopa may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00322
Carbidopa may decrease the excretion rate of Floxuridine which could result in a higher serum level.
DB00323
Carbidopa may decrease the excretion rate of Tolcapone which could result in a higher serum level.
DB00327
Carbidopa may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
DB00330
Carbidopa may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00331
Carbidopa may decrease the excretion rate of Metformin which could result in a higher serum level.
DB00333
Carbidopa may decrease the excretion rate of Methadone which could result in a higher serum level.
DB00339
Carbidopa may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00341
Carbidopa may decrease the excretion rate of Cetirizine which could result in a higher serum level.
DB00349
Carbidopa may decrease the excretion rate of Clobazam which could result in a higher serum level.
DB00351
Carbidopa may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
DB00355
Carbidopa may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00356
Carbidopa may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
DB00359
Carbidopa may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
DB00364
Carbidopa may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00372
Carbidopa may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
DB00377
Carbidopa may decrease the excretion rate of Palonosetron which could result in a higher serum level.
DB00380
Carbidopa may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DB00398
Carbidopa may decrease the excretion rate of Sorafenib which could result in a higher serum level.
DB00402
Carbidopa may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
DB00404
Carbidopa may decrease the excretion rate of Alprazolam which could result in a higher serum level.
DB00412
Carbidopa may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
DB00413
Carbidopa may decrease the excretion rate of Pramipexole which could result in a higher serum level.
DB00415
Carbidopa may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00418
Carbidopa may decrease the excretion rate of Secobarbital which could result in a higher serum level.
DB00432
Carbidopa may decrease the excretion rate of Trifluridine which could result in a higher serum level.
DB00435
Carbidopa may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
DB00437
Carbidopa may decrease the excretion rate of Allopurinol which could result in a higher serum level.
DB00440
Carbidopa may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
DB00441
Carbidopa may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
DB00476
Carbidopa may decrease the excretion rate of Duloxetine which could result in a higher serum level.
DB00480
Carbidopa may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
DB00490
Carbidopa may decrease the excretion rate of Buspirone which could result in a higher serum level.
DB00499
Carbidopa may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00501
Carbidopa may decrease the excretion rate of Cimetidine which could result in a higher serum level.
DB00535
Carbidopa may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00537
Carbidopa may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
DB00548
Carbidopa may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00553
Carbidopa may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00555
Carbidopa may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
DB00558
Carbidopa may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00569
Carbidopa may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
DB00583
Carbidopa may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00591
Carbidopa may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
DB00597
Carbidopa may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00603
Carbidopa may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
DB00608
Carbidopa may decrease the excretion rate of Chloroquine which could result in a higher serum level.
DB00624
Carbidopa may decrease the excretion rate of Testosterone which could result in a higher serum level.
DB00628
Carbidopa may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
DB00631
Carbidopa may decrease the excretion rate of Clofarabine which could result in a higher serum level.
DB00633
Carbidopa may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
DB00635
Carbidopa may decrease the excretion rate of Prednisone which could result in a higher serum level.
DB00651
Carbidopa may decrease the excretion rate of Dyphylline which could result in a higher serum level.
DB00660
Carbidopa may decrease the excretion rate of Metaxalone which could result in a higher serum level.
DB00661
Carbidopa may decrease the excretion rate of Verapamil which could result in a higher serum level.
DB00665
Carbidopa may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00669
Carbidopa may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
DB00672
Carbidopa may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
DB00683
Carbidopa may decrease the excretion rate of Midazolam which could result in a higher serum level.
DB00688
Carbidopa may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
DB00690
Carbidopa may decrease the excretion rate of Flurazepam which could result in a higher serum level.
DB00698
Carbidopa may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00706
Carbidopa may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00709
Carbidopa may decrease the excretion rate of Lamivudine which could result in a higher serum level.
DB00713
Carbidopa may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00716
Carbidopa may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00730
Carbidopa may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00731
Carbidopa may decrease the excretion rate of Nateglinide which could result in a higher serum level.
DB00733
Carbidopa may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00743
Carbidopa may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
DB00759
Carbidopa may decrease the excretion rate of Tetracycline which could result in a higher serum level.
DB00760
Carbidopa may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00761
Carbidopa may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
DB00763
Carbidopa may decrease the excretion rate of Methimazole which could result in a higher serum level.
DB00775
Carbidopa may decrease the excretion rate of Tirofiban which could result in a higher serum level.
DB00780
Carbidopa may decrease the excretion rate of Phenelzine which could result in a higher serum level.
DB00782
Carbidopa may decrease the excretion rate of Propantheline which could result in a higher serum level.
DB00783
Carbidopa may decrease the excretion rate of Estradiol which could result in a higher serum level.
DB00789
Carbidopa may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00804
Carbidopa may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
DB00806
Carbidopa may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
DB00811
Carbidopa may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00828
Carbidopa may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00829
Carbidopa may decrease the excretion rate of Diazepam which could result in a higher serum level.
DB00839
Carbidopa may decrease the excretion rate of Tolazamide which could result in a higher serum level.
DB00841
Carbidopa may decrease the excretion rate of Dobutamine which could result in a higher serum level.
DB00842
Carbidopa may decrease the excretion rate of Oxazepam which could result in a higher serum level.
DB00851
Carbidopa may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
DB00853
Carbidopa may decrease the excretion rate of Temozolomide which could result in a higher serum level.
DB00863
Carbidopa may decrease the excretion rate of Ranitidine which could result in a higher serum level.
DB00871
Carbidopa may decrease the excretion rate of Terbutaline which could result in a higher serum level.
DB00894
Carbidopa may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00897
Carbidopa may decrease the excretion rate of Triazolam which could result in a higher serum level.
DB00900
Carbidopa may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00911
Carbidopa may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00915
Carbidopa may decrease the excretion rate of Amantadine which could result in a higher serum level.
DB00918
Carbidopa may decrease the excretion rate of Almotriptan which could result in a higher serum level.
DB00928
Carbidopa may decrease the excretion rate of Azacitidine which could result in a higher serum level.
DB00934
Carbidopa may decrease the excretion rate of Maprotiline which could result in a higher serum level.
DB00951
Carbidopa may decrease the excretion rate of Isoniazid which could result in a higher serum level.
DB00953
Carbidopa may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
DB00961
Carbidopa may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00962
Carbidopa may decrease the excretion rate of Zaleplon which could result in a higher serum level.
DB00980
Carbidopa may decrease the excretion rate of Ramelteon which could result in a higher serum level.
DB00988
Carbidopa may decrease the excretion rate of Dopamine which could result in a higher serum level.
DB00993
Carbidopa may decrease the excretion rate of Azathioprine which could result in a higher serum level.
DB00995
Carbidopa may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB01001
Carbidopa may decrease the excretion rate of Salbutamol which could result in a higher serum level.
DB01002
Carbidopa may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB01004
Carbidopa may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
DB01010
Carbidopa may decrease the excretion rate of Edrophonium which could result in a higher serum level.
DB01011
Carbidopa may decrease the excretion rate of Metyrapone which could result in a higher serum level.
DB01015
Carbidopa may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.
DB01020
Carbidopa may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB01022
Carbidopa may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB01024
Carbidopa may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
DB01030
Carbidopa may decrease the excretion rate of Topotecan which could result in a higher serum level.
DB01032
Carbidopa may decrease the excretion rate of Probenecid which could result in a higher serum level.
DB01036
Carbidopa may decrease the excretion rate of Tolterodine which could result in a higher serum level.
DB01039
Carbidopa may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
DB01043
Carbidopa may decrease the excretion rate of Memantine which could result in a higher serum level.
DB01046
Carbidopa may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB01048
Carbidopa may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB01060
Carbidopa may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB01067
Carbidopa may decrease the excretion rate of Glipizide which could result in a higher serum level.
DB01068
Carbidopa may decrease the excretion rate of Clonazepam which could result in a higher serum level.
DB01069
Carbidopa may decrease the excretion rate of Promethazine which could result in a higher serum level.
DB01093
Carbidopa may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
DB01099
Carbidopa may decrease the excretion rate of Flucytosine which could result in a higher serum level.
DB01101
Carbidopa may decrease the excretion rate of Capecitabine which could result in a higher serum level.
DB01105
Carbidopa may decrease the excretion rate of Sibutramine which could result in a higher serum level.
DB01115
Carbidopa may decrease the excretion rate of Nifedipine which could result in a higher serum level.
DB01124
Carbidopa may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
DB01129
Carbidopa may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
DB01133
Carbidopa may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
DB01135
Carbidopa may decrease the excretion rate of Doxacurium which could result in a higher serum level.
DB01137
Carbidopa may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
DB01148
Carbidopa may decrease the excretion rate of Flavoxate which could result in a higher serum level.
DB01149
Carbidopa may decrease the excretion rate of Nefazodone which could result in a higher serum level.
DB01157
Carbidopa may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB01166
Carbidopa may decrease the excretion rate of Cilostazol which could result in a higher serum level.
DB01169
Carbidopa may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.
DB01181
Carbidopa may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
DB01183
Carbidopa may decrease the excretion rate of Naloxone which could result in a higher serum level.
DB01205
Carbidopa may decrease the excretion rate of Flumazenil which could result in a higher serum level.
DB01213
Carbidopa may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB01215
Carbidopa may decrease the excretion rate of Estazolam which could result in a higher serum level.
DB01221
Carbidopa may decrease the excretion rate of Ketamine which could result in a higher serum level.
DB01222
Carbidopa may decrease the excretion rate of Budesonide which could result in a higher serum level.
DB01241
Carbidopa may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
DB01249
Carbidopa may decrease the excretion rate of Iodixanol which could result in a higher serum level.
DB01261
Carbidopa may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
DB01273
Carbidopa may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB01274
Carbidopa may decrease the excretion rate of Arformoterol which could result in a higher serum level.
DB01367
Carbidopa may decrease the excretion rate of Rasagiline which could result in a higher serum level.
DB01394
Carbidopa may decrease the excretion rate of Colchicine which could result in a higher serum level.
DB01409
Carbidopa may decrease the excretion rate of Tiotropium which could result in a higher serum level.
DB01420
Carbidopa may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
DB01427
Carbidopa may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB01428
Carbidopa may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB01431
Carbidopa may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
DB01550
Carbidopa may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB01558
Carbidopa may decrease the excretion rate of Bromazepam which could result in a higher serum level.
DB01563
Carbidopa may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
DB01577
Carbidopa may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
DB01587
Carbidopa may decrease the excretion rate of Ketazolam which could result in a higher serum level.
DB01610
Carbidopa may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
DB01638
Carbidopa may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB01656
Carbidopa may decrease the excretion rate of Roflumilast which could result in a higher serum level.
DB01685
Carbidopa may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
DB04574
Carbidopa may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
DB04871
Carbidopa may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
DB04895
Carbidopa may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB04896
Carbidopa may decrease the excretion rate of Milnacipran which could result in a higher serum level.
DB04920
Carbidopa may decrease the excretion rate of Clevidipine which could result in a higher serum level.
DB04953
Carbidopa may decrease the excretion rate of Ezogabine which could result in a higher serum level.
DB05018
Carbidopa may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB05541
Carbidopa may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
DB05676
Carbidopa may decrease the excretion rate of Apremilast which could result in a higher serum level.
DB06154
Carbidopa may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB06186
Carbidopa may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB06196
Carbidopa may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB06203
Carbidopa may decrease the excretion rate of Alogliptin which could result in a higher serum level.
DB06209
Carbidopa may decrease the excretion rate of Prasugrel which could result in a higher serum level.
DB06211
Carbidopa may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB06228
Carbidopa may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
DB06230
Carbidopa may decrease the excretion rate of Nalmefene which could result in a higher serum level.
DB06282
Carbidopa may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
DB06335
Carbidopa may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
DB06402
Carbidopa may decrease the excretion rate of Telavancin which could result in a higher serum level.
DB06480
Carbidopa may decrease the excretion rate of Prucalopride which could result in a higher serum level.
DB06623
Carbidopa may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB06637
Carbidopa may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
DB06695
Carbidopa may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
DB06700
Carbidopa may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
DB06702
Carbidopa may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
DB06705
Carbidopa may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB06710
Carbidopa may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
DB06767
Carbidopa may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
DB06782
Carbidopa may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB06796
Carbidopa may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB06800
Carbidopa may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB06809
Carbidopa may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB06813
Carbidopa may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
DB06823
Carbidopa may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB06824
Carbidopa may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB08824
Carbidopa may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB08826
Carbidopa may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB08840
Carbidopa may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB08872
Carbidopa may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
DB08877
Carbidopa may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
DB08893
Carbidopa may decrease the excretion rate of Mirabegron which could result in a higher serum level.
DB08894
Carbidopa may decrease the excretion rate of Peginesatide which could result in a higher serum level.
DB08897
Carbidopa may decrease the excretion rate of Aclidinium which could result in a higher serum level.
DB08899
Carbidopa may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
DB08900
Carbidopa may decrease the excretion rate of Teduglutide which could result in a higher serum level.
DB08904
Carbidopa may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
DB08905
Carbidopa may decrease the excretion rate of Formestane which could result in a higher serum level.
DB08909
Carbidopa may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
DB08910
Carbidopa may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
DB08911
Carbidopa may decrease the excretion rate of Trametinib which could result in a higher serum level.
DB08918
Carbidopa may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
DB08934
Carbidopa may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB09027
Carbidopa may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB09050
Carbidopa may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB09066
Carbidopa may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
DB09068
Carbidopa may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
DB09071
Carbidopa may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
DB09075
Carbidopa may decrease the excretion rate of Edoxaban which could result in a higher serum level.
DB09081
Carbidopa may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB09082
Carbidopa may decrease the excretion rate of Vilanterol which could result in a higher serum level.
DB09089
Carbidopa may decrease the excretion rate of Trimebutine which could result in a higher serum level.
DB09091
Carbidopa may decrease the excretion rate of Tixocortol which could result in a higher serum level.
DB09103
Carbidopa may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB09104
Carbidopa may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
DB09106
Carbidopa may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB09111
Carbidopa may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB09118
Carbidopa may decrease the excretion rate of Stiripentol which could result in a higher serum level.
DB09121
Carbidopa may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB09123
Carbidopa may decrease the excretion rate of Dienogest which could result in a higher serum level.
DB09129
Carbidopa may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB09132
Carbidopa may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB09133
Carbidopa may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB09134
Carbidopa may decrease the excretion rate of Ioversol which could result in a higher serum level.
DB09135
Carbidopa may decrease the excretion rate of Ioxilan which could result in a higher serum level.
DB09136
Carbidopa may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB09137
Carbidopa may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB09139
Carbidopa may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB09148
Carbidopa may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB09149
Carbidopa may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB09156
Carbidopa may decrease the excretion rate of Iopromide which could result in a higher serum level.
DB09163
Carbidopa may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB09165
Carbidopa may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB09185
Carbidopa may decrease the excretion rate of Viloxazine which could result in a higher serum level.
DB09194
Carbidopa may decrease the excretion rate of Etoperidone which could result in a higher serum level.
DB09195
Carbidopa may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
DB09204
Carbidopa may decrease the excretion rate of Arotinolol which could result in a higher serum level.
DB09205
Carbidopa may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB09209
Carbidopa may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB09210
Carbidopa may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB09219
Carbidopa may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB09241
Carbidopa may decrease the excretion rate of Methylene blue which could result in a higher serum level.
DB09244
Carbidopa may decrease the excretion rate of Pirlindole which could result in a higher serum level.
DB09245
Carbidopa may decrease the excretion rate of Toloxatone which could result in a higher serum level.
DB09255
Carbidopa may decrease the excretion rate of Dextran which could result in a higher serum level.
DB09256
Carbidopa may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB09257
Carbidopa may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB09262
Carbidopa may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
DB09264
Carbidopa may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB09265
Carbidopa may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
DB09268
Carbidopa may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB09276
Carbidopa may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
DB09277
Carbidopa may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
DB09281
Carbidopa may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
DB09292
Carbidopa may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB09301
Carbidopa may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB09317
Carbidopa may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB09318
Carbidopa may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB09320
Carbidopa may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB09324
Carbidopa may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB09325
Carbidopa may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB09329
Carbidopa may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB09344
Carbidopa may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB09357
Carbidopa may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB09394
Carbidopa may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB09395
Carbidopa may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB09407
Carbidopa may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB09418
Carbidopa may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
DB09472
Carbidopa may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB09481
Carbidopa may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
DB09488
Carbidopa may decrease the excretion rate of Acrivastine which could result in a higher serum level.
DB09496
Carbidopa may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB09502
Carbidopa may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB09546
Carbidopa may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB09570
Carbidopa may decrease the excretion rate of Ixazomib which could result in a higher serum level.
DB11077
Carbidopa may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB11090
Carbidopa may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB11098
Carbidopa may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB11102
Carbidopa may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB11114
Carbidopa may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB11127
Carbidopa may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB11130
Carbidopa may decrease the excretion rate of Opium which could result in a higher serum level.
DB11135
Carbidopa may decrease the excretion rate of Selenium which could result in a higher serum level.
DB11136
Carbidopa may decrease the excretion rate of Chromium which could result in a higher serum level.
DB11145
Carbidopa may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB11156
Carbidopa may decrease the excretion rate of Pyrantel which could result in a higher serum level.
DB11164
Carbidopa may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB11251
Carbidopa may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB11278
Carbidopa may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB11328
Carbidopa may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB11338
Carbidopa may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB11358
Carbidopa may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
DB11364
Carbidopa may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB11560
Carbidopa may decrease the excretion rate of Lesinurad which could result in a higher serum level.
DB11577
Carbidopa may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB11587
Carbidopa may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB11598
Carbidopa may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
DB11642
Carbidopa may decrease the excretion rate of Pitolisant which could result in a higher serum level.
DB11691
Carbidopa may decrease the excretion rate of Naldemedine which could result in a higher serum level.
DB11699
Carbidopa may decrease the excretion rate of Tropisetron which could result in a higher serum level.
DB11817
Carbidopa may decrease the excretion rate of Baricitinib which could result in a higher serum level.
DB11901
Carbidopa may decrease the excretion rate of Apalutamide which could result in a higher serum level.
DB11915
Carbidopa may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB11943
Carbidopa may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
DB11989
Carbidopa may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB12007
Carbidopa may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB12107
Carbidopa may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB12161
Carbidopa may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
DB12278
Carbidopa may decrease the excretion rate of Propiverine which could result in a higher serum level.
DB12783
Carbidopa may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB13025
Carbidopa may decrease the excretion rate of Tiapride which could result in a higher serum level.
DB13139
Carbidopa may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
DB13156
Carbidopa may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB13178
Carbidopa may decrease the excretion rate of Inositol which could result in a higher serum level.
DB13185
Carbidopa may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB13191
Carbidopa may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB13269
Carbidopa may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB13293
Carbidopa may decrease the excretion rate of Ipecac which could result in a higher serum level.
DB13595
Carbidopa may decrease the excretion rate of Almasilate which could result in a higher serum level.
DB13873
Carbidopa may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
DB13884
Carbidopa may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB13909
Carbidopa may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB13943
Carbidopa may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
DB13944
Carbidopa may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
DB13946
Carbidopa may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
DB13952
Carbidopa may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
DB13954
Carbidopa may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
DB13955
Carbidopa may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
DB13956
Carbidopa may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
DB13967
Carbidopa may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB14006
Carbidopa may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
DB14007
Carbidopa may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB14498
Carbidopa may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB14499
Carbidopa may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB14526
Carbidopa may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB14527
Carbidopa may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB14528
Carbidopa may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB14529
Carbidopa may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB14530
Carbidopa may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB14754
Carbidopa may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
DB06815
Carbidopa may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB11121
Carbidopa may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB11085
Carbidopa may decrease the excretion rate of Resorcinol which could result in a higher serum level.
DB15593
Carbidopa may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB00318
Carbidopa may decrease the excretion rate of Codeine which could result in a higher serum level.
DB00454
Carbidopa may decrease the excretion rate of Meperidine which could result in a higher serum level.
DB00813
Carbidopa may decrease the excretion rate of Fentanyl which could result in a higher serum level.
DB00879
Carbidopa may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB14506
Carbidopa may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
DB13987
Carbidopa may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
DB04890
Carbidopa may decrease the excretion rate of Bepotastine which could result in a higher serum level.
DB00982
Carbidopa may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB04930
Carbidopa may decrease the excretion rate of Permethrin which could result in a higher serum level.
DB09095
Carbidopa may decrease the excretion rate of Difluocortolone which could result in a higher serum level.
DB00479
Amikacin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00684
Tobramycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00798
Gentamicin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00955
Netilmicin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00994
Neomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01082
Streptomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB01172
Kanamycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB03615
Ribostamycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB04729
Gentamicin C1a may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB06696
Arbekacin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB12604
Sisomicin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB13540
Isepamicin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00552
Carbidopa may decrease the excretion rate of Pentostatin which could result in a higher serum level.
DB13145
Carbidopa may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00314
Carbidopa may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00390
Carbidopa may decrease the excretion rate of Digoxin which could result in a higher serum level.
DB00512
Carbidopa may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00515
Carbidopa may decrease the excretion rate of Cisplatin which could result in a higher serum level.
DB00564
Carbidopa may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
DB00642
Carbidopa may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
DB00682
Carbidopa may decrease the excretion rate of Warfarin which could result in a higher serum level.
DB00908
Carbidopa may decrease the excretion rate of Quinidine which could result in a higher serum level.
DB01035
Carbidopa may decrease the excretion rate of Procainamide which could result in a higher serum level.
DB12615
Carbidopa may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB14509
Carbidopa may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
DB00803
Colistin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00887
Carbidopa may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
DB00909
Carbidopa may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
DB08907
Carbidopa may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
DB09338
Carbidopa may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB00232
Methyclothiazide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB00311
Ethoxzolamide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB00421
Spironolactone may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB00562
Benzthiazide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB00594
Amiloride may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB00703
Methazolamide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB00819
Acetazolamide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB00872
Conivaptan may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB01144
Diclofenamide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB01325
Quinethazone may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB01395
Drospirenone may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB01412
Theobromine may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB02925
Piretanide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB05034
Ularitide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB06212
Tolvaptan may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB06292
Dapagliflozin may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB06370
Indisulam may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB08961
Azosemide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB09015
Canrenoic acid may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB09125
Potassium citrate may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB09401
Isosorbide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB11827
Ertugliflozin may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB12221
Canrenone may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB12670
Rolofylline may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB12704
Spiradoline may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB13284
Meticrane may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB13405
Mefruside may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB13430
Mebutizide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB13617
Clorexolone may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB13663
Clofenamide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB13708
Fenquizone may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB13792
Clopamide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB13989
Epitizide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB14018
Bromotheophylline may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB14500
Potassium may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB01345
Carbidopa may increase the excretion rate of Potassium cation which could result in a lower serum level and potentially a reduction in efficacy.
DB00579
The risk or severity of adverse effects can be increased when Mazindol is combined with Carbidopa.
DB00177
The risk or severity of hypotension can be increased when Carbidopa is combined with Valsartan.
DB00178
The risk or severity of hypotension can be increased when Carbidopa is combined with Ramipril.
DB00187
The risk or severity of hypotension can be increased when Carbidopa is combined with Esmolol.
DB00195
The risk or severity of hypotension can be increased when Carbidopa is combined with Betaxolol.
DB00206
The risk or severity of hypotension can be increased when Carbidopa is combined with Reserpine.
DB00212
The risk or severity of hypotension can be increased when Carbidopa is combined with Remikiren.
DB00214
The risk or severity of hypotension can be increased when Carbidopa is combined with Torasemide.
DB00217
The risk or severity of hypotension can be increased when Carbidopa is combined with Bethanidine.
DB00226
The risk or severity of hypotension can be increased when Carbidopa is combined with Guanadrel.
DB00264
The risk or severity of hypotension can be increased when Carbidopa is combined with Metoprolol.
DB00270
The risk or severity of hypotension can be increased when Carbidopa is combined with Isradipine.
DB00275
The risk or severity of hypotension can be increased when Carbidopa is combined with Olmesartan.
DB00310
The risk or severity of hypotension can be increased when Carbidopa is combined with Chlorthalidone.
DB00325
The risk or severity of hypotension can be increased when Carbidopa is combined with Nitroprusside.
DB00335
The risk or severity of hypotension can be increased when Carbidopa is combined with Atenolol.
DB00343
The risk or severity of hypotension can be increased when Carbidopa is combined with Diltiazem.
DB00350
The risk or severity of hypotension can be increased when Carbidopa is combined with Minoxidil.
DB00373
The risk or severity of hypotension can be increased when Carbidopa is combined with Timolol.
DB00374
The risk or severity of hypotension can be increased when Carbidopa is combined with Treprostinil.
DB00381
The risk or severity of hypotension can be increased when Carbidopa is combined with Amlodipine.
DB00393
The risk or severity of hypotension can be increased when Carbidopa is combined with Nimodipine.
DB00401
The risk or severity of hypotension can be increased when Carbidopa is combined with Nisoldipine.
DB00436
The risk or severity of hypotension can be increased when Carbidopa is combined with Bendroflumethiazide.
DB00457
The risk or severity of hypotension can be increased when Carbidopa is combined with Prazosin.
DB00492
The risk or severity of hypotension can be increased when Carbidopa is combined with Fosinopril.
DB00519
The risk or severity of hypotension can be increased when Carbidopa is combined with Trandolapril.
DB00524
The risk or severity of hypotension can be increased when Carbidopa is combined with Metolazone.
DB00528
The risk or severity of hypotension can be increased when Carbidopa is combined with Lercanidipine.
DB00542
The risk or severity of hypotension can be increased when Carbidopa is combined with Benazepril.
DB00559
The risk or severity of hypotension can be increased when Carbidopa is combined with Bosentan.
DB00571
The risk or severity of hypotension can be increased when Carbidopa is combined with Propranolol.
DB00575
The risk or severity of hypotension can be increased when Carbidopa is combined with Clonidine.
DB00584
The risk or severity of hypotension can be increased when Carbidopa is combined with Enalapril.
DB00590
The risk or severity of hypotension can be increased when Carbidopa is combined with Doxazosin.
DB00598
The risk or severity of hypotension can be increased when Carbidopa is combined with Labetalol.
DB00606
The risk or severity of hypotension can be increased when Carbidopa is combined with Cyclothiazide.
DB00612
The risk or severity of hypotension can be increased when Carbidopa is combined with Bisoprolol.
DB00616
The risk or severity of hypotension can be increased when Carbidopa is combined with Candoxatril.
DB00622
The risk or severity of hypotension can be increased when Carbidopa is combined with Nicardipine.
DB00629
The risk or severity of hypotension can be increased when Carbidopa is combined with Guanabenz.
DB00657
The risk or severity of hypotension can be increased when Carbidopa is combined with Mecamylamine.
DB00678
The risk or severity of hypotension can be increased when Carbidopa is combined with Losartan.
DB00691
The risk or severity of hypotension can be increased when Carbidopa is combined with Moexipril.
DB00692
The risk or severity of hypotension can be increased when Carbidopa is combined with Phentolamine.
DB00700
The risk or severity of hypotension can be increased when Carbidopa is combined with Eplerenone.
DB00722
The risk or severity of hypotension can be increased when Carbidopa is combined with Lisinopril.
DB00727
The risk or severity of hypotension can be increased when Carbidopa is combined with Nitroglycerin.
DB00765
The risk or severity of hypotension can be increased when Carbidopa is combined with Metyrosine.
DB00774
The risk or severity of hypotension can be increased when Carbidopa is combined with Hydroflumethiazide.
DB00785
The risk or severity of hypotension can be increased when Carbidopa is combined with Cryptenamine.
DB00790
The risk or severity of hypotension can be increased when Carbidopa is combined with Perindopril.
DB00796
The risk or severity of hypotension can be increased when Carbidopa is combined with Candesartan cilexetil.
DB00797
The risk or severity of hypotension can be increased when Carbidopa is combined with Tolazoline.
DB00800
The risk or severity of hypotension can be increased when Carbidopa is combined with Fenoldopam.
DB00808
The risk or severity of hypotension can be increased when Carbidopa is combined with Indapamide.
DB00820
The risk or severity of hypotension can be increased when Carbidopa is combined with Tadalafil.
DB00866
The risk or severity of hypotension can be increased when Carbidopa is combined with Alprenolol.
DB00876
The risk or severity of hypotension can be increased when Carbidopa is combined with Eprosartan.
DB00880
The risk or severity of hypotension can be increased when Carbidopa is combined with Chlorothiazide.
DB00881
The risk or severity of hypotension can be increased when Carbidopa is combined with Quinapril.
DB00886
The risk or severity of hypotension can be increased when Carbidopa is combined with Omapatrilat.
DB00925
The risk or severity of hypotension can be increased when Carbidopa is combined with Phenoxybenzamine.
DB00960
The risk or severity of hypotension can be increased when Carbidopa is combined with Pindolol.
DB00966
The risk or severity of hypotension can be increased when Carbidopa is combined with Telmisartan.
DB00968
The risk or severity of hypotension can be increased when Carbidopa is combined with Methyldopa.
DB00999
The risk or severity of hypotension can be increased when Carbidopa is combined with Hydrochlorothiazide.
DB01018
The risk or severity of hypotension can be increased when Carbidopa is combined with Guanfacine.
DB01021
The risk or severity of hypotension can be increased when Carbidopa is combined with Trichlormethiazide.
DB01023
The risk or severity of hypotension can be increased when Carbidopa is combined with Felodipine.
DB01029
The risk or severity of hypotension can be increased when Carbidopa is combined with Irbesartan.
DB01054
The risk or severity of hypotension can be increased when Carbidopa is combined with Nitrendipine.
DB01089
The risk or severity of hypotension can be increased when Carbidopa is combined with Deserpidine.
DB01090
The risk or severity of hypotension can be increased when Carbidopa is combined with Pentolinium.
DB01116
The risk or severity of hypotension can be increased when Carbidopa is combined with Trimethaphan.
DB01119
The risk or severity of hypotension can be increased when Carbidopa is combined with Diazoxide.
DB01136
The risk or severity of hypotension can be increased when Carbidopa is combined with Carvedilol.
DB01158
The risk or severity of hypotension can be increased when Carbidopa is combined with Bretylium.
DB01162
The risk or severity of hypotension can be increased when Carbidopa is combined with Terazosin.
DB01170
The risk or severity of hypotension can be increased when Carbidopa is combined with Guanethidine.
DB01180
The risk or severity of hypotension can be increased when Carbidopa is combined with Rescinnamine.
DB01193
The risk or severity of hypotension can be increased when Carbidopa is combined with Acebutolol.
DB01197
The risk or severity of hypotension can be increased when Carbidopa is combined with Captopril.
DB01203
The risk or severity of hypotension can be increased when Carbidopa is combined with Nadolol.
DB01240
The risk or severity of hypotension can be increased when Carbidopa is combined with Epoprostenol.
DB01244
The risk or severity of hypotension can be increased when Carbidopa is combined with Bepridil.
DB01275
The risk or severity of hypotension can be increased when Carbidopa is combined with Hydralazine.
DB01295
The risk or severity of hypotension can be increased when Carbidopa is combined with Bevantolol.
DB01297
The risk or severity of hypotension can be increased when Carbidopa is combined with Practolol.
DB01324
The risk or severity of hypotension can be increased when Carbidopa is combined with Polythiazide.
DB01340
The risk or severity of hypotension can be increased when Carbidopa is combined with Cilazapril.
DB01347
The risk or severity of hypotension can be increased when Carbidopa is combined with Saprisartan.
DB01348
The risk or severity of hypotension can be increased when Carbidopa is combined with Spirapril.
DB01359
The risk or severity of hypotension can be increased when Carbidopa is combined with Penbutolol.
DB01388
The risk or severity of hypotension can be increased when Carbidopa is combined with Mibefradil.
DB01580
The risk or severity of hypotension can be increased when Carbidopa is combined with Oxprenolol.
DB01626
The risk or severity of hypotension can be increased when Carbidopa is combined with Pargyline.
DB03322
The risk or severity of hypotension can be increased when Carbidopa is combined with Dexpropranolol.
DB04831
The risk or severity of hypotension can be increased when Carbidopa is combined with Tienilic acid.
DB04840
The risk or severity of hypotension can be increased when Carbidopa is combined with Debrisoquine.
DB04846
The risk or severity of hypotension can be increased when Carbidopa is combined with Celiprolol.
DB04861
The risk or severity of hypotension can be increased when Carbidopa is combined with Nebivolol.
DB04948
The risk or severity of hypotension can be increased when Carbidopa is combined with Lofexidine.
DB06268
The risk or severity of hypotension can be increased when Carbidopa is combined with Sitaxentan.
DB06403
The risk or severity of hypotension can be increased when Carbidopa is combined with Ambrisentan.
DB06445
The risk or severity of hypotension can be increased when Carbidopa is combined with Diethylnorspermine.
DB06712
The risk or severity of hypotension can be increased when Carbidopa is combined with Nilvadipine.
DB06762
The risk or severity of hypotension can be increased when Carbidopa is combined with Pinacidil.
DB07767
The risk or severity of hypotension can be increased when Carbidopa is combined with Ferulic acid.
DB08808
The risk or severity of hypotension can be increased when Carbidopa is combined with Bupranolol.
DB08836
The risk or severity of hypotension can be increased when Carbidopa is combined with Temocapril.
DB08931
The risk or severity of hypotension can be increased when Carbidopa is combined with Riociguat.
DB08932
The risk or severity of hypotension can be increased when Carbidopa is combined with Macitentan.
DB08950
The risk or severity of hypotension can be increased when Carbidopa is combined with Indoramin.
DB08952
The risk or severity of hypotension can be increased when Carbidopa is combined with Indenolol.
DB08960
The risk or severity of hypotension can be increased when Carbidopa is combined with Hexamethonium.
DB09026
The risk or severity of hypotension can be increased when Carbidopa is combined with Aliskiren.
DB09206
The risk or severity of hypotension can be increased when Carbidopa is combined with Trimazosin.
DB09220
The risk or severity of hypotension can be increased when Carbidopa is combined with Nicorandil.
DB09235
The risk or severity of hypotension can be increased when Carbidopa is combined with Efonidipine.
DB09236
The risk or severity of hypotension can be increased when Carbidopa is combined with Lacidipine.
DB09238
The risk or severity of hypotension can be increased when Carbidopa is combined with Manidipine.
DB09239
The risk or severity of hypotension can be increased when Carbidopa is combined with Niguldipine.
DB09242
The risk or severity of hypotension can be increased when Carbidopa is combined with Moxonidine.
DB09363
The risk or severity of hypotension can be increased when Carbidopa is combined with Rauwolfia serpentina root.
DB09477
The risk or severity of hypotension can be increased when Carbidopa is combined with Enalaprilat.
DB11362
The risk or severity of hypotension can be increased when Carbidopa is combined with Selexipag.
DB11720
The risk or severity of hypotension can be increased when Carbidopa is combined with Angiotensin 1-7.
DB11738
The risk or severity of hypotension can be increased when Carbidopa is combined with Rilmenidine.
DB11770
The risk or severity of hypotension can be increased when Carbidopa is combined with Talinolol.
DB11783
The risk or severity of hypotension can be increased when Carbidopa is combined with Imidapril.
DB12054
The risk or severity of hypotension can be increased when Carbidopa is combined with BQ-123.
DB12092
The risk or severity of hypotension can be increased when Carbidopa is combined with Naftopidil.
DB12093
The risk or severity of hypotension can be increased when Carbidopa is combined with Tetrahydropalmatine.
DB12212
The risk or severity of hypotension can be increased when Carbidopa is combined with Landiolol.
DB12465
The risk or severity of hypotension can be increased when Carbidopa is combined with Ketanserin.
DB12661
The risk or severity of hypotension can be increased when Carbidopa is combined with Urapidil.
DB12766
The risk or severity of hypotension can be increased when Carbidopa is combined with Cicletanine.
DB12945
The risk or severity of hypotension can be increased when Carbidopa is combined with Dihydralazine.
DB13166
The risk or severity of hypotension can be increased when Carbidopa is combined with Zofenopril.
DB13211
The risk or severity of hypotension can be increased when Carbidopa is combined with Guanoxan.
DB13312
The risk or severity of hypotension can be increased when Carbidopa is combined with Delapril.
DB13374
The risk or severity of hypotension can be increased when Carbidopa is combined with Vincamine.
DB13400
The risk or severity of hypotension can be increased when Carbidopa is combined with Linsidomine.
DB13410
The risk or severity of hypotension can be increased when Carbidopa is combined with Guanoxabenz.
DB13429
The risk or severity of hypotension can be increased when Carbidopa is combined with Tolonidine.
DB13435
The risk or severity of hypotension can be increased when Carbidopa is combined with Endralazine.
DB13443
The risk or severity of hypotension can be increased when Carbidopa is combined with Esatenolol.
DB13452
The risk or severity of hypotension can be increased when Carbidopa is combined with Cadralazine.
DB13508
The risk or severity of hypotension can be increased when Carbidopa is combined with Cloranolol.
DB13532
The risk or severity of hypotension can be increased when Carbidopa is combined with Cyclopenthiazide.
DB13575
The risk or severity of hypotension can be increased when Carbidopa is combined with Bietaserpine.
DB13604
The risk or severity of hypotension can be increased when Carbidopa is combined with Guanazodine.
DB13631
The risk or severity of hypotension can be increased when Carbidopa is combined with Methoserpidine.
DB13757
The risk or severity of hypotension can be increased when Carbidopa is combined with Epanolol.
DB13779
The risk or severity of hypotension can be increased when Carbidopa is combined with Guanoclor.
DB13801
The risk or severity of hypotension can be increased when Carbidopa is combined with Muzolimine.
DB13803
The risk or severity of hypotension can be increased when Carbidopa is combined with Xipamide.
DB13919
The risk or severity of hypotension can be increased when Carbidopa is combined with Candesartan.
DB14068
The risk or severity of hypotension can be increased when Carbidopa is combined with Dexniguldipine.
DB14094
The risk or severity of hypotension can be increased when Carbidopa is combined with Tocopherylquinone.
DB14125
The risk or severity of hypotension can be increased when Carbidopa is combined with Benazeprilat.
DB14207
The risk or severity of hypotension can be increased when Carbidopa is combined with Fosinoprilat.
DB14208
The risk or severity of hypotension can be increased when Carbidopa is combined with Ramiprilat.
DB14213
The risk or severity of hypotension can be increased when Carbidopa is combined with Perindoprilat.
DB14217
The risk or severity of hypotension can be increased when Carbidopa is combined with Quinaprilat.
DB00695
The risk or severity of hypotension can be increased when Carbidopa is combined with Furosemide.
DB09237
The risk or severity of hypotension can be increased when Carbidopa is combined with Levamlodipine.
DB00321
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Amitriptyline.
DB00344
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Protriptyline.
DB00458
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Imipramine.
DB00540
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Nortriptyline.
DB00543
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Amoxapine.
DB00726
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Trimipramine.
DB01142
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Doxepin.
DB01151
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Desipramine.
DB01242
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Clomipramine.
DB04836
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Amineptine.
DB08996
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Dimetacrine.
DB09016
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Butriptyline.
DB09167
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Dosulepin.
DB09289
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Tianeptine.
DB09307
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Oxaprotiline.
DB12930
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Opipramol.
DB13114
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Amitriptylinoxide.
DB13225
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Dibenzepin.
DB13246
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Quinupramine.
DB13384
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Melitracen.
DB13411
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Lofepramine.
DB13496
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Iprindole.
DB13782
The risk or severity of hypertension and tardive dyskinesia can be increased when Carbidopa is combined with Imipramine oxide.
DB00893
Iron Dextran can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01592
Iron can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06215
Ferumoxytol can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06783
Prussian blue can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08917
Ferric carboxymaltose can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09146
Iron sucrose can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09147
Ferric pyrophosphate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09501
Ferric ammonium citrate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09507
Ferumoxsil can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09508
Ferumoxides can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11171
Ferric sulfate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11210
Ferrous bisglycinate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11417
Gleptoferron can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11576
Ferric oxide can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12821
Perflubutane can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13257
Ferrous sulfate anhydrous can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13381
Sodium feredetate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13423
Ferric hydroxide can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13569
Ferrous chloride can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13949
Ferric cation can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14488
Ferrous gluconate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14489
Ferrous succinate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14491
Ferrous fumarate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14520
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14695
Ferric oxyhydroxide can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB15598
Ferric maltol can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12208
Iron isomaltoside 1000 can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13848
The bioavailability of Fluorodopa (18F) can be increased when combined with Carbidopa.